Issues in patient compliance.

Abstract:

:Patient compliance refers to the willingness and ability of an individual to follow health-related advice, to take medication as prescribed, to attend scheduled clinic appointments and to complete recommended investigations. It is a major health issue, with outcomes related to levels of morbidity, mortality and cost utilisation. Poor compliance has been reported as the most common cause of nonresponse to medication, with evidence to show that patients who adhere to treatment recommendations have better health outcomes than those who do not adhere, even when taking a placebo. Evidence-based practice guidelines, founded on clinical, behavioural and educational concepts, provide a means of measuring outcomes related to health status, patient satisfaction and cost-benefit issues, and may help to ensure that responsibility for compliance is shared between the clinician and the patient.

journal_name

Drugs

journal_title

Drugs

authors

Murphy J,Coster G

doi

10.2165/00003495-199754060-00002

subject

Has Abstract

pub_date

1997-12-01 00:00:00

pages

797-800

issue

6

eissn

0012-6667

issn

1179-1950

journal_volume

54

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Optimum management of nausea and vomiting in cancer chemotherapy.

    abstract::Nausea and vomiting continue to be critical problems in cancer chemotherapy, although considerable progress has been made toward understanding the neuropharmacological mechanisms of vomiting and how chemotherapeutic agents and antiemetics affect these mechanisms. The principles of behavioural psychology have also been...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198734010-00005

    authors: Triozzi PL,Laszlo J

    更新日期:1987-07-01 00:00:00

  • Epidemiology of high blood pressure and obesity.

    abstract::The relationship between bodyweight and arterial pressure was first discovered early this century. More recently, epidemiological studies have confirmed the correlation between bodyweight and blood pressure in both adults and children. Serum cholesterol levels, blood glucose levels, uric acid levels and blood pressure...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300462-00025

    authors: Martínez FJ,Sancho-Rof JM

    更新日期:1993-01-01 00:00:00

  • Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.

    abstract::Buflomedil hydrochloride is a vasoactive drug with a variety of pharmacodynamic properties. Importantly, it seems to improve nutritional blood flow in ischaemic tissue of patients with peripheral and/or cerebral vascular disease by a combination of pharmacological effects: inhibition of alpha-adrenoceptors, inhibition...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198733050-00002

    authors: Clissold SP,Lynch S,Sorkin EM

    更新日期:1987-05-01 00:00:00

  • Vitamin A acid: a review of its pharmacological properties and therapeutic use in the topical treatment of acne vulgaris.

    abstract::Vitamin A acid (retinoic acid: tretinoin) is a vitamin A derivative used in the topical treatment of acne. It acts by 'unseating' comedones, improvement developing slowly over a period of 2 to 3 or more months, and is also said to prevent the formation of new lesions. About three-quarters of patients with acne vulgari...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714060-00001

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-12-01 00:00:00

  • Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity.

    abstract::Childhood obesity has become the most common paediatric disorder in the developed world. Treatment of obesity in children may include lifestyle interventions, pharmacotherapy and weight-loss supplements. The outcome of lifestyle interventions, which classically include dietary modifications, increased activity and beh...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11319210-000000000-00000

    authors: Rogovik AL,Chanoine JP,Goldman RD

    更新日期:2010-02-12 00:00:00

  • Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

    abstract:UNLABELLED:Patients with beta-thalassaemia and other transfusion-dependent diseases develop iron overload from chronic blood transfusions and require regular iron chelation to prevent potentially fatal iron-related complications. The only iron chelator currently widely available is deferoxamine, which is expensive and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00021

    authors: Barman Balfour JA,Foster RH

    更新日期:1999-09-01 00:00:00

  • Oxantel-pyrantel in various regimens for the treatment of soil transmitted helminthiasis in rural and urban communities.

    abstract::204 individuals from a rural community were given a single dose of oxantel-pyrantel at 15mg/kg bodyweight and if still infected, 20mg/kg bodyweight, with cure rates of 100%, 53% and 71% for ascariasis, trichuriasis and hookworm infection, respectively. From an urban community, 124 patients were given the same drug eit...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-197800151-00016

    authors: Cabrera BD,Sy FS

    更新日期:1978-01-01 00:00:00

  • [The kidney as a target organ in diabetic patients with arterial hypertension].

    abstract::Diabetes mellitus has become the most common single cause of end-stage renal disease in the Western world. Diabetic nephropathy, as most forms of renal disease leading to end-stage renal failure, is frequently complicated by arterial hypertension. In type 1 diabetes mellitus the reported excess in arterial hypertensio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Viberti G

    更新日期:2003-01-01 00:00:00

  • Lixisenatide: first global approval.

    abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0033-3

    authors: Elkinson S,Keating GM

    更新日期:2013-03-01 00:00:00

  • Quinupristin-dalfopristin.

    abstract::Quinupristin-dalfopristin (RP 59500) is an injectable streptogramin antibiotic. It possesses a wide spectrum of activity against Gram-positive bacteria including methicillin-resistant staphylococci, glycopeptide-resistant. Enterococcus faecium and penicillin-resistant pneumococci. Quinupristin-dalfopristin has activit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652030-00006

    authors: Bryson HM,Spencer CM

    更新日期:1996-09-01 00:00:00

  • Idiopathic membranous nephropathy: management strategies.

    abstract::Treatment of idiopathic membranous nephropathy is based on a 'symptomatic' therapy that includes ACE inhibitors or angiotensin II receptor antagonists, and on an 'aetiological' therapy aimed at modulating underlying immunological mechanisms. The role of the latter is still debated given the usually indolent course of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969100-00002

    authors: Quaglia M,Stratta P

    更新日期:2009-07-09 00:00:00

  • Airway and lung remodelling in chronic pulmonary obstructive disease: a role for muscarinic receptor antagonists?

    abstract::Lung tissue remodelling in chronic inflammatory lung diseases has long been regarded as a follow-up event to inflammation. Recent studies have indicated that, although airway and lung tissue remodelling is often independent of inflammation, it precedes or causes inflammation. None of the available therapies has a sign...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0319-0

    authors: Roth M

    更新日期:2015-01-01 00:00:00

  • Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.

    abstract::Matrix metalloproteinases (MMPs) are a family of functionally related zinc-containing enzymes that denature and degrade fibrillar collagens and other components of the extracellular matrix. Myocardial extracellular matrix remodelling and fibrosis regulated by MMPs are believed to be important contributors to the progr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161090-00002

    authors: Li YY,Feldman AM

    更新日期:2001-01-01 00:00:00

  • Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.

    abstract::Although venous thromboembolism has occasionally been reported after hospital discharge in patients who have undergone total hip replacement (THR), this risk has not been fully quantified and the usefulness of a prophylactic treatment has not been evaluated. We conducted a single-centre prospective randomised double-b...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199600527-00009

    authors: Planes A,Vochelle N,Darmon JY,Fagola M,Bellaud M,Compan D,Saliba E,Weisslinger N,Huet Y

    更新日期:1996-01-01 00:00:00

  • Platelets, thrombosis and drugs.

    abstract::The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is he...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197509010-00003

    authors: Mustard JF,Packham MA

    更新日期:1975-01-01 00:00:00

  • Schistosomiasis drug therapy and treatment considerations.

    abstract::Schistosomiasis, a grave and debilitating disease of socioeconomic importance, is increasing in incidence despite concerted efforts to control and contain the disease in all the endemic areas. While a multipronged method of control using health education, sanitation and snail control has been used, chemotherapy and ch...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199142030-00004

    authors: Shekhar KC

    更新日期:1991-09-01 00:00:00

  • New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.

    abstract::A gradual rise in drug-resistant trends among Gram-negative organisms, especially carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide. In the last decade, many pharmaceutica...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01112-1

    authors: Jean SS,Gould IM,Lee WS,Hsueh PR,International Society of Antimicrobial Chemotherapy (ISAC).

    更新日期:2019-05-01 00:00:00

  • Sacituzumab Govitecan: First Approval.

    abstract::Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01337-5

    authors: Syed YY

    更新日期:2020-07-01 00:00:00

  • The prevalence of hypertension in the United States today.

    abstract::The simplest response to the question, what is the prevalence of hypertension in the United States today?, is given by a currently popular slogan: 23,000,000 Americans have hypertension. It is clear that the problem is large in scale, but this figure alone is an insufficient guide to many practical issues. The prevale...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197600111-00006

    authors: Labarthe DR

    更新日期:1976-01-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0960-0

    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • Hypopigmentary skin disorders: current treatment options and future directions.

    abstract::Alterations of skin and hair pigmentation are important features that have warranted treatment from ancient history on up to modern time. In some cultures, even today patients with vitiligo are regarded as social outcasts and are affected considerably both emotionally and physically. This article presents current opti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464010-00006

    authors: Hartmann A,Bröcker EB,Becker JC

    更新日期:2004-01-01 00:00:00

  • Albumin-bound Paclitaxel: in metastatic breast cancer.

    abstract::A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distributi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200666070-00007

    authors: Robinson DM,Keating GM

    更新日期:2006-01-01 00:00:00

  • Vasodilatation with pinacidil. Mode of action in rat resistance vessels.

    abstract::Pinacidil is a newly developed antihypertensive vasodilator, proposed to belong to the new group of smooth muscle relaxants, the K+ channel openers. The in vitro effects of pinacidil on induced tone, smooth muscle membrane potential and 86Rb and 42K efflux from rat resistance vessels (internal diameter about 200 micro...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800367-00006

    authors: Videbaek LM,Aalkjaer C,Mulvany MJ

    更新日期:1988-01-01 00:00:00

  • Methotrexate in rheumatoid arthritis. An update.

    abstract::Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by several regulatory agencies, including the Food and Drug Administration. The tendency is now to prescribe it at earlier stages of the disease. Methotrexate is a well known antifolate. Its exact mechanism of action in rheumatoid arth...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447010-00003

    authors: Bannwarth B,Labat L,Moride Y,Schaeverbeke T

    更新日期:1994-01-01 00:00:00

  • The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure.

    abstract::As first reported by our group in 1975, severe heart failure due to idiopathic dilated cardiomyopathy could be improved in patients receiving beta-blocker therapy starting at a very low dose and followed by a stepwise increase. Since then, these results have been confirmed by our own group and by others, and similar r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400474-00006

    authors: Hjalmarson A,Waagstein F

    更新日期:1994-01-01 00:00:00

  • Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.

    abstract::Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464230-00005

    authors: Keating GM,Plosker GL

    更新日期:2004-01-01 00:00:00

  • Induction therapy in renal transplant recipients: how convincing is the current evidence?

    abstract::The goal of organ transplantation is to provide durable organ function while minimizing risks such as infection and cancer. Induction therapy in renal transplantation provides improved short- and long-term graft outcomes compared with placebo. Three agents are currently available and widely used in the US; rabbit anti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11631300-000000000-00000

    authors: Wagner SJ,Brennan DC

    更新日期:2012-03-26 00:00:00

  • Valsartan/hydrochlorothiazide.

    abstract::Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate. HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957050-00008

    authors: Langtry HD,McClellan KJ

    更新日期:1999-05-01 00:00:00

  • Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

    abstract::The rapid spread of human immunodeficiency virus (HIV) infections and the grim outcome of these infections have focused interest on the possibilities for medical intervention. The end-stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198734030-00004

    authors: Sandström EG,Kaplan JC

    更新日期:1987-09-01 00:00:00

  • Effects of ketanserin tartrate on serum lipids in patients with essential hypertension.

    abstract::Several antihypertensive agents such as thiazide diuretics and some beta-blockers have recently been shown to adversely affect lipid metabolism. Moreover, there is a growing suspicion that the adverse effect on plasma lipids might outweigh the favourable effect of lowering blood pressure. The effect of ketanserin tart...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198800361-00006

    authors: Nakamura H,Hirata F,Yasugi T,Mizuno M,Saito E,Ishikawa T,Tada N,Nakaya N,Homma Y,Takeuchi I

    更新日期:1988-01-01 00:00:00